Karen Ballack > Weil, Gotshal & Manges LLP > Redwood Shores, United States > Lawyer Profile

Weil, Gotshal & Manges LLP
United States
Karen Ballack photo




Karen Ballack is an intellectual property transactional attorney with emphasis on representing technology companies, particularly in the computer (hardware and software), Internet, semiconductor, biotechnology, pharmaceutical and medical device industries. Karen is also a member of Weil’s Privacy & Cybersecurity group and is based in the Silicon Valley office. Karen has extensive experience in a wide variety of complex technology and intellectual property alliances and transactions. Representative matters include: licensing arrangements; research and development collaborations; joint ventures; strategic alliances and corporate partnering transactions; intellectual property acquisitions and divestitures; manufacture and supply arrangements; distribution and reseller arrangements; co‑marketing alliances; consulting and professional services agreements; and other arrangements involving the commercial exploitation of technology and intellectual property. Karen’s practice also includes providing intellectual property assistance in connection with private equity, M&A and other corporate transactions. Karen is frequently engaged as a guest speaker on topics relating to technology and intellectual property transactions.


San Diego State University (B.S., summa cum laude, 1981); University of San Francisco (J.D., 1986).

Lawyer Rankings

United States > Media, technology and telecoms > Technology transactions

Weil, Gotshal & Manges LLP has extremely good experience representing companies and investors operating in the technology and life sciences industries. The team has developed good credentials for standalone technology and IP deals, including advice on patent acquisitions and divestitures, licensing arrangements, research and development collaborations, and technology and IP-focused joint ventures and strategic alliances. A recent highlight included advising Eli Lilly and Company on a license agreement to acquire exclusive global rights to antibody-drug conjugates for the targeted treatment of cancer  from ImmunoGen. This expertise feeds through into the broader support the team provides to the corporate finance group, including advice on corporate M&A and private equity buyouts, banking and finance transactions, and restructuring matters. Jeffrey Osterman  and Charan Sandhu  jointly lead the market-leading team, which also includes Karen Ballack  in Silicon Valley, and the department’s founder and former head, Michael Epstein. All partners are based in New York unless otherwise stated.